or
Remember me
Back
"We will continue to leverage our leading clinical position and our team's long and successful track record in R&D to engage large pharmaceutical companies and advance the development and eventual distribution of Braxia products…We are prioritizing the expansion of our clinics in North America and the development of ketamine derivatives and IP-capable delivery systems in order to create value for shareholders through this RD&I approach, while building upon a strong foundation with good corporate governance at its core."
A daily snapshot of everything from market open to close.